A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results - PubMed
Treatment with ritlecitinib or brepocitinib for 24 weeks was efficacious and generally well tolerated.